Compare GLDD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | PHAT |
|---|---|---|
| Founded | 1890 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.6M | 942.6M |
| IPO Year | 2006 | 2019 |
| Metric | GLDD | PHAT |
|---|---|---|
| Price | $13.37 | $17.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.33 |
| AVG Volume (30 Days) | 400.7K | ★ 870.6K |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.27 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $834,599,000.00 | $147,190,000.00 |
| Revenue This Year | $12.71 | $220.37 |
| Revenue Next Year | $4.77 | $83.14 |
| P/E Ratio | $11.22 | ★ N/A |
| Revenue Growth | 12.53 | ★ 460.30 |
| 52 Week Low | $7.51 | $2.21 |
| 52 Week High | $14.02 | $18.31 |
| Indicator | GLDD | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 66.74 |
| Support Level | $13.28 | $16.77 |
| Resistance Level | $13.60 | $18.31 |
| Average True Range (ATR) | 0.36 | 0.88 |
| MACD | -0.06 | 0.26 |
| Stochastic Oscillator | 43.10 | 79.95 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.